Imran Chaudhary

516 total citations
29 papers, 391 citations indexed

About

Imran Chaudhary is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Imran Chaudhary has authored 29 papers receiving a total of 391 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 9 papers in Cancer Research and 7 papers in Molecular Biology. Recurrent topics in Imran Chaudhary's work include Colorectal Cancer Treatments and Studies (10 papers), Cancer Treatment and Pharmacology (10 papers) and Cancer Genomics and Diagnostics (7 papers). Imran Chaudhary is often cited by papers focused on Colorectal Cancer Treatments and Studies (10 papers), Cancer Treatment and Pharmacology (10 papers) and Cancer Genomics and Diagnostics (7 papers). Imran Chaudhary collaborates with scholars based in United States, Australia and Spain. Imran Chaudhary's co-authors include Sanjay Goel, Mohammad H. Ghalib, Umang Swami, Sridhar Mani, Matthew Coffey, George M. Gill, Kavita Desai, Mark H. Einstein, K.L. Mettinger and John M. Mariadason and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Imran Chaudhary

27 papers receiving 379 citations

Peers

Countries citing papers authored by Imran Chaudhary

Since Specialization

Citations

This map shows the geographic impact of Imran Chaudhary's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Imran Chaudhary with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Imran Chaudhary more than expected).

Fields of papers citing papers by Imran Chaudhary

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Imran Chaudhary. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Imran Chaudhary. The network helps show where Imran Chaudhary may publish in the future.

Co-authorship network of co-authors of Imran Chaudhary

This figure shows the co-authorship network connecting the top 25 collaborators of Imran Chaudhary. A scholar is included among the top collaborators of Imran Chaudhary based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Imran Chaudhary. Imran Chaudhary is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes Among Racial and Ethnic Minority Patients With Advanced Cancers in Phase 1 Trials 2024 ·JAMA Network Open ·Sanjay Goel, Abdissa Negassa, Mohammad H. Ghalib, Imran Chaudhary, Kavita Desai, Umang Shah, Umang Swami, (unknown), Radhashree Maitra, Sridhar Mani	0
2	A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors 2024 ·Investigational New Drugs ·Mohammad H. Ghalib, Mariano Provencio, Maria J. de Miguel, Virginia Calvo, Imran Chaudhary, M Bakri Hammami, (unknown), Radhashree Maitra, Sara Martínez, Carmen Kahatt, (unknown), Salvador Fudio, Sanjay Goel	0
3	Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS -Mutated Colorectal Cancer 2020 ·Molecular Cancer Therapeutics ·Sanjay Goel, Allyson J. Ocean, (unknown), Mohammad H. Ghalib, Imran Chaudhary, Umang Shah, (unknown), (unknown), Matthew Coffey, Radhashree Maitra	25
4	Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer 2020 ·Clinical Cancer Research ·(unknown), (unknown), Devika Rao, (unknown), (unknown), (unknown), (unknown), Imran Chaudhary, Titto Augustine, Sanjay Goel, Radhashree Maitra	37
5	Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin 2019 ·Oncotarget ·Devika Rao, Atrayee Basu Mallick, Titto Augustine, (unknown), (unknown), (unknown), Imran Chaudhary, Raviraja N. Seetharam, Arjun B. Sood, (unknown), Santiago Aparo, Lakshmi Rajdev, Andreas Kaubisch, (unknown), Abdissa Negassa, John M. Mariadason, Radhashree Maitra, Sanjay Goel	11
6	Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials 2018 ·Investigational New Drugs ·Audrey E. Kam, Gopichand Pendurti, Umang Shah, Mohammad H. Ghalib, Imran Chaudhary, (unknown), Lakshmi Rajdev, Andreas Kaubisch, Santiago Aparo, Ioannis Mantzaris, Sanjay Goel	6
7	Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer 2017 ·Clinical Colorectal Cancer ·Sanjay Goel, Abdissa Negassa, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Umang Shah, Imran Chaudhary, Mohammad H. Ghalib, Lakshmi Rajdev, Andreas Kaubisch, (unknown), Santiago Aparo	5
8	A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS-mutant metastatic colorectal cancer (mCRC). 2013 ·Journal of Clinical Oncology ·Allyson J. Ocean, Tanios Bekaii‐Saab, Imran Chaudhary, (unknown), Paul J. Christos, (unknown), Erika Florendo, (unknown), Joseph T. Ruggiero, E Popa, Melissa L. Wilson, Mohammad H. Ghalib, (unknown), Umang Shah, Lakshmi Rajdev, (unknown), George M. Gill, Matthew Coffey, Manish A. Shah, Sanjay Goel	9
9	Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: A single institution experience from 1999 to 2010 2013 ·Gynecologic Oncology ·June Y. Hou, Santiago Aparo, Mohammad H. Ghalib, Imran Chaudhary, Umang Shah, Umang Swami, Mark H. Einstein, Gary L. Goldberg, Sridhar Mani, Sanjay Goel	6
10	Safety, pharmacokinetics, and activity of EZN‐2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies 2012 ·Cancer ·Razelle Kurzrock, Sanjay Goel, Jennifer J. Wheler, David S. Hong, Siqing Fu, Keyvan Rezaï, (unknown), Saı̈k Urien, Sridhar Mani, Imran Chaudhary, (unknown), Aby Buchbinder, François Lokiec, Mary F. Mulcahy	38
11	Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors. 2012 ·Journal of Clinical Oncology ·Sanjay Goel, Teresa Morán, (unknown), Santiago Viteri, Imran Chaudhary, Mohammad H. Ghalib, Umang Swami, (unknown), Enric Carcereny, (unknown), (unknown), (unknown), Cristina Bugés, Rafael Rosell	2
12	Eribulin—A review of preclinical and clinical studies 2011 ·Critical Reviews in Oncology/Hematology ·Umang Swami, Imran Chaudhary, Mohammad H. Ghalib, Sanjay Goel	78
13	A phase I study of the novel DNA topoisomerase-1 inhibitor, TLC388, administered intravenously to patients with advanced solid tumors. 2011 ·Journal of Clinical Oncology ·Sharad Ghamande, Chih‐Hung Lin, (unknown), Teresa A. Coleman, Imran Chaudhary, (unknown), Michael H. Silverman, Min‐Liang Kuo, (unknown), (unknown), (unknown), Sanjay Goel	4
14	Final results of a phase I dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors. 2011 ·Journal of Clinical Oncology ·T Ohnuma, J F Holland, (unknown), Eric Wilck, Deborah Lehrer, Mohammad H. Ghalib, Imran Chaudhary, François Wilhelm, Umang Swami, (unknown)	4
15	Phase I dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors. 2010 ·Journal of Clinical Oncology ·Imran Chaudhary, Lakshmi Rajdev, Umang Swami, François Wilhelm, (unknown), Missak Haigentz, Andreas Kaubisch, Shom Goel, Sridhar Mani, Mohammad H. Ghalib	1
16	Alterations of chemotherapeutic pharmacokinetic profiles by drug–drug interactions 2009 ·Expert Opinion on Drug Metabolism & Toxicology ·Sridhar Mani, (unknown), Imran Chaudhary, Sanjay Goel	8
17	Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors 2009 ·Investigational New Drugs ·(unknown), Mohammad H. Ghalib, Kavita Desai, Imran Chaudhary, (unknown), Mark H. Einstein, Matthew Coffey, George M. Gill, K.L. Mettinger, John M. Mariadason, Sridhar Mani, Sanjay Goel	116
18	Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers 2006 ·Investigational New Drugs ·Sanjay Goel, Kavita Desai, (unknown), (unknown), Imran Chaudhary, (unknown), Andreas Kaubisch, Gary L. Goldberg, Mark H. Einstein, Fernando Camacho, Sharyn D. Baker, Sridhar Mani	6
19	Effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone 2006 ·Journal of Clinical Oncology ·Sanjay Goel, Gary L. Goldberg, Lisa Iacono, M. Cohen, T. Griffin, (unknown), Kavita Desai, Imran Chaudhary, Sridhar Mani	5
20	Evolution in the practice of primary angioplasty: Effect of adjunctive coronary stenting and glycoprotein IIb/IIIa inhibitors on long‐term outcomes 2001 ·Catheterization and Cardiovascular Interventions ·Vijay G. Kalaria, Imran Chaudhary, (unknown), Richard M. Pomerantz, (unknown), Frederick S. Ling, Donald E. Cutlip	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact